Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
50M
-
Number of holders
-
79
-
Total 13F shares, excl. options
-
14.7M
-
Shares change
-
+139K
-
Total reported value, excl. options
-
$278M
-
Value change
-
+$4.36M
-
Put/Call ratio
-
1.25
-
Number of buys
-
42
-
Number of sells
-
-27
-
Price
-
$18.99
Significant Holders of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) as of Q4 2020
91 filings reported holding KALV - KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share as of Q4 2020.
KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) has 79 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 14.7M shares
of 50M outstanding shares and own 29.33% of the company stock.
Largest 10 shareholders include EVENTIDE ASSET MANAGEMENT, LLC (1.68M shares), FMR LLC (1.64M shares), Vivo Capital, LLC (1.62M shares), BlackRock Inc. (1.11M shares), Ikarian Capital, LLC (1.06M shares), WELLINGTON MANAGEMENT GROUP LLP (873K shares), PICTET ASSET MANAGEMENT LTD (847K shares), VANGUARD GROUP INC (568K shares), Logos Global Management LP (490K shares), and Opaleye Management Inc. (470K shares).
This table shows the top 79 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.